TY - JOUR
T1 - Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma
AU - Strati, Paolo
AU - Nastoupil, Loretta J.
AU - Westin, Jason
AU - Fayad, Luis E.
AU - Ahmed, Sairah
AU - Fowler, Nathan H.
AU - Hagemeister, Fredrick B.
AU - Lee, Hun J.
AU - Iyer, Swaminathan P.
AU - Nair, Ranjit
AU - Parmar, Simrit
AU - Rodriguez, Maria A.
AU - Samaniego, Felipe
AU - Steiner, Raphael E.
AU - Wang, Michael
AU - Pinnix, Chelsea C.
AU - Adkins, Sherry
AU - Claussen, Catherine M.
AU - Martinez, Charles S.
AU - Hawkins, Misha C.
AU - Johnson, Nicole A.
AU - Singh, Prachee
AU - Mistry, Haleigh E.
AU - Horowitz, Sandra
AU - George, Shirley
AU - Feng, Lei
AU - Kebriaei, Partow
AU - Shpall, Elizabeth J.
AU - Neelapu, Sattva S.
AU - Tummala, Sudhakar
AU - Chi, T. Linda
N1 - Publisher Copyright:
© 2020 by The American Society of Hematology.
PY - 2020/8/25
Y1 - 2020/8/25
N2 - Neurotoxicity or immune effector cell-associated neurotoxicity syndrome (ICANS) is the second most common acute toxicity after chimeric antigen receptor (CAR) T-cell therapy. However, there are limited data on the clinical and radiologic correlates of ICANS. We conducted a cohort analysis of 100 consecutive patients with relapsed or refractory large B-cell lymphoma (LBCL) treated with standard of care axicabtagene ciloleucel (axi-cel). ICANS was graded according to an objective grading system. Neuroimaging studies and electroencephalograms (EEGs) were reviewed by an expert neuroradiologist and neurologist. Of 100 patients included in the study, 68 (68%) developed ICANS of any grade and 41 (41%) had grade $3. Median time to ICANS onset was 5 days, and median duration was 6 days. ICANS grade $3 was associated with high peak ferritin (P 5 .03) and C-reactive protein (P 5 .001) levels and a low peak monocyte count (P 5 .001) within the 30 days after axi-cel infusion. Magnetic resonance imaging was performed in 38 patients with ICANS and revealed 4 imaging patterns with features of encephalitis (n 5 7), stroke (n 5 3), leptomeningeal disease (n 5 2), and posterior reversible encephalopathy syndrome (n 5 2). Abnormalities noted on EEG included diffuse slowing (n 5 49), epileptiform discharges (n 5 6), and nonconvulsive status epilepticus (n 5 8). Although reversible, grade $3 ICANS was associated with significantly shorter progression-free (P 5 .02) and overall survival (progression being the most common cause of death; P 5 .001). Our results suggest that imaging and EEG abnormalities are common in patients with ICANS, and high-grade ICANS is associated with worse outcome after CAR T-cell therapy in LBCL patients.
AB - Neurotoxicity or immune effector cell-associated neurotoxicity syndrome (ICANS) is the second most common acute toxicity after chimeric antigen receptor (CAR) T-cell therapy. However, there are limited data on the clinical and radiologic correlates of ICANS. We conducted a cohort analysis of 100 consecutive patients with relapsed or refractory large B-cell lymphoma (LBCL) treated with standard of care axicabtagene ciloleucel (axi-cel). ICANS was graded according to an objective grading system. Neuroimaging studies and electroencephalograms (EEGs) were reviewed by an expert neuroradiologist and neurologist. Of 100 patients included in the study, 68 (68%) developed ICANS of any grade and 41 (41%) had grade $3. Median time to ICANS onset was 5 days, and median duration was 6 days. ICANS grade $3 was associated with high peak ferritin (P 5 .03) and C-reactive protein (P 5 .001) levels and a low peak monocyte count (P 5 .001) within the 30 days after axi-cel infusion. Magnetic resonance imaging was performed in 38 patients with ICANS and revealed 4 imaging patterns with features of encephalitis (n 5 7), stroke (n 5 3), leptomeningeal disease (n 5 2), and posterior reversible encephalopathy syndrome (n 5 2). Abnormalities noted on EEG included diffuse slowing (n 5 49), epileptiform discharges (n 5 6), and nonconvulsive status epilepticus (n 5 8). Although reversible, grade $3 ICANS was associated with significantly shorter progression-free (P 5 .02) and overall survival (progression being the most common cause of death; P 5 .001). Our results suggest that imaging and EEG abnormalities are common in patients with ICANS, and high-grade ICANS is associated with worse outcome after CAR T-cell therapy in LBCL patients.
UR - http://www.scopus.com/inward/record.url?scp=85090339046&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090339046&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2020002228
DO - 10.1182/bloodadvances.2020002228
M3 - Article
C2 - 32822484
AN - SCOPUS:85090339046
SN - 2473-9529
VL - 4
SP - 3943
EP - 3951
JO - Blood Advances
JF - Blood Advances
IS - 16
ER -